Refractory anemia with excess blasts in transformation
MONDO:0015692Refractory anemia with excess blasts in transformation (RAEB-T) is characterized by dysplastic features of the myeloid and usually erythroid progenitor cells in the bone marrow and an increased number of myeloblasts in the peripheral blood. The peripheral blood blast count ranges from 20% to 30%. RAEB-T used to be a subcategory of myelodysplastic syndromes in the past. Recently, the term has been eliminated from the WHO based classification of myelodysplastic syndromes. The reason is that the percentage of peripheral blood blasts required for the diagnosis of acute myeloid leukemia has been reduced to 20%. The elimination of the RAEB-T term by the WHO experts has created confusion and ongoing arguments. Currently, according to WHO classification, the vast majority of RAEB-T cases are best classified as acute leukemias (acute leukemias with multilineage dysplasia following myelodysplastic syndrome). A minority of cases are part of RAEB-2.
Also known as: RAEB-T, RAEB-t
1868 clinical trials for this condition and its sub-types, 6 tagged with Refractory anemia with excess blasts in transformation itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Intense Pre-Transplant combo shows promise for tough leukemias
Disease control CompletedThis phase 2 trial tested a combination of intravenous busulfan, etoposide, and low-dose total-body irradiation before a donor stem cell or bone marrow transplant in 30 patients with advanced leukemia or myelodysplastic syndromes. The goal was to see how well this regimen control…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Tailoring chemo by genetics and health may boost survival in older AML patients
Disease control CompletedThis study tested whether matching chemotherapy intensity to a patient's genetic risk and overall health could improve outcomes for older adults (60+) with acute myeloid leukemia. 75 participants received either standard intensive or lower-intensity chemo based on their individua…
Phase 2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC